FDA Panel Recommends At-Home Colon Cancer Test
DNA analysis of stool boosts accuracy rate of Cologuard to more than 90 percent, researchers say
WebMD News Archive
By Alan Mozes
FRIDAY, March 28, 2014 (HealthDay News) -- A panel of U.S. Food and Drug Administration experts on Thursday unanimously recommended approval of a new at-home stool test that screens for colorectal cancer with more than 90 percent accuracy.
The 10-member committee said the benefits of Exact Science Corp.'s Cologuard test outweigh its risks, the Associated Press reported. The FDA is not obligated to follow its panels' recommendations, but usually does.
The panel's blessing comes on the heels of a study published earlier this month that found Cologuard had a very high accuracy rate in spotting colon cancer.
Last year, nearly 143,000 new cases of colorectal cancer were diagnosed in the United States and almost 50,000 Americans died of the disease, according to the U.S. National Cancer Institute.
Yet, one-third of Americans fail to heed public health recommendations to undergo more invasive colonoscopy screenings every 10 years starting at age 50, said study co-author Dr. Steven Itzkowitz, director of the gastroenterology fellowship program at the Icahn School of Medicine at Mount Sinai in New York City
Commonly used stool tests such as FIT (fecal immunochemical testing) rely on detecting blood in the stool. The new Cologuard test checks for blood as well as abnormal DNA coming from the tumor, "with the advantage that some lesions, even cancers, don't bleed very much," Itzkowitz explained.
The Cologuard test also features a DNA analysis not included in other fecal exams.
"By increasing the pick-up rate in this way," said Itzkowitz, "we found that the new test had a 92 percent sensitivity for detection of colorectal cancer. That kind of result is really unprecedented for a noninvasive stool-based screening."
The research, published in the March 19 issue of the New England Journal of Medicine, was funded by Exact Sciences, which is based in Wisconsin.
To assess the potential of the DNA method, nearly 10,000 men and women aged 50 and older were screened for colon cancer and precancerous polyps at one of 90 sites across the United States and Canada. All were considered at average risk for colon cancer.